UA73745C2 - Use of il-18 inhibitors for preparing pharmaceutical composition inhibiting tumor metastasis - Google Patents

Use of il-18 inhibitors for preparing pharmaceutical composition inhibiting tumor metastasis Download PDF

Info

Publication number: UA73745C2
Authority: UA; Ukraine
Prior art keywords: cells; sep; adhesion; apa; inhibitors
Prior art date: 1999-07-22

Application number

UA2002021472A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-22

Filing date

2000-07-17

Publication date

2005-09-15

2000-07-17 Application filed filed Critical

2005-09-15 Publication of UA73745C2 publication Critical patent/UA73745C2/uk

Links

206010027476 Metastases Diseases 0.000 title abstract description 19
239000003112 inhibitor Substances 0.000 title abstract description 17
206010028980 Neoplasm Diseases 0.000 title abstract description 10
230000009401 metastasis Effects 0.000 title abstract description 5
239000008194 pharmaceutical composition Substances 0.000 title description 4
230000002401 inhibitory effect Effects 0.000 title 1
108090000171 Interleukin-18 Proteins 0.000 abstract description 69
210000004027 cell Anatomy 0.000 description 97
101001052500 Homo sapiens Membrane metallo-endopeptidase-like 1 Proteins 0.000 description 72
101001067174 Homo sapiens Plexin-B1 Proteins 0.000 description 72
102100024197 Membrane metallo-endopeptidase-like 1 Human genes 0.000 description 72
229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 72
241000699670 Mus sp. Species 0.000 description 24
238000004519 manufacturing process Methods 0.000 description 20
210000004185 liver Anatomy 0.000 description 18
108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
102000004127 Cytokines Human genes 0.000 description 14
108090000695 Cytokines Proteins 0.000 description 14
238000002474 experimental method Methods 0.000 description 12
241001529936 Murinae Species 0.000 description 11
102000004557 Interleukin-18 Receptors Human genes 0.000 description 9
108010017537 Interleukin-18 Receptors Proteins 0.000 description 9
230000000694 effects Effects 0.000 description 9
102100036352 Protein disulfide-isomerase Human genes 0.000 description 8
230000009471 action Effects 0.000 description 7
230000004913 activation Effects 0.000 description 7
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000000770 proinflammatory effect Effects 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
230000021164 cell adhesion Effects 0.000 description 5
102000044166 interleukin-18 binding protein Human genes 0.000 description 5
108010070145 interleukin-18 binding protein Proteins 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
201000001441 melanoma Diseases 0.000 description 5
102100035904 Caspase-1 Human genes 0.000 description 4
108090000426 Caspase-1 Proteins 0.000 description 4
101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 4
102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 4
230000003305 autocrine Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000031037 interleukin-18 production Effects 0.000 description 3
210000005228 liver tissue Anatomy 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000001629 suppression Effects 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102100039065 Interleukin-1 beta Human genes 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
230000002950 deficient Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000037353 metabolic pathway Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
-1 6-carboxy-fluorescein acetoxymethyl ester Chemical class 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
235000008375 Decussocarpus nagi Nutrition 0.000 description 1
244000309456 Decussocarpus nagi Species 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
101100434616 Mus musculus Akna gene Proteins 0.000 description 1
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000004712 cancer cell adhesion Effects 0.000 description 1
210000001043 capillary endothelial cell Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
238000010217 densitometric analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002224 dissection Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000013038 irreversible inhibitor Substances 0.000 description 1
230000000684 melanotic effect Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2002021472A 1999-07-22 2000-07-17 Use of il-18 inhibitors for preparing pharmaceutical composition inhibiting tumor metastasis UA73745C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL13104799A IL131047A0 (en)	1999-07-22	1999-07-22	Use of il-18 inhibitors
PCT/IL2000/000419 WO2001007480A2 (en)	1999-07-22	2000-07-17	Use of interleukin-18 inhibitors to inhibit tumor metastasis

Publications (1)

Publication Number	Publication Date
UA73745C2 true UA73745C2 (en)	2005-09-15

Family

ID=11073044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002021472A UA73745C2 (en)	1999-07-22	2000-07-17	Use of il-18 inhibitors for preparing pharmaceutical composition inhibiting tumor metastasis

Country Status (31)

Country	Link
US (1)	US7741276B2 (pt)
EP (1)	EP1206274B1 (pt)
JP (1)	JP4827352B2 (pt)
KR (1)	KR100682219B1 (pt)
CN (1)	CN1173736C (pt)
AR (1)	AR024907A1 (pt)
AT (1)	ATE363288T1 (pt)
AU (1)	AU782478B2 (pt)
BG (1)	BG65800B1 (pt)
BR (1)	BR0012675A (pt)
CA (1)	CA2380216C (pt)
CY (1)	CY1107932T1 (pt)
CZ (1)	CZ302114B6 (pt)
DE (2)	DE1206274T1 (pt)
DK (1)	DK1206274T3 (pt)
EA (1)	EA005419B1 (pt)
EE (1)	EE04838B1 (pt)
ES (1)	ES2186596T3 (pt)
HK (1)	HK1048248B (pt)
HU (1)	HU228780B1 (pt)
IL (2)	IL131047A0 (pt)
MX (1)	MXPA02000838A (pt)
NO (1)	NO329827B1 (pt)
NZ (1)	NZ516535A (pt)
PL (1)	PL202477B1 (pt)
PT (1)	PT1206274E (pt)
SK (1)	SK287522B6 (pt)
TR (1)	TR200200169T2 (pt)
UA (1)	UA73745C2 (pt)
WO (1)	WO2001007480A2 (pt)
ZA (1)	ZA200200390B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001236807A1 (en)	2000-02-10	2001-08-20	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
US6894155B2 (en)	2000-10-11	2005-05-17	Viron Therapeutics	Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en)	2000-12-04	2010-05-18	Viron Therapeutics Inc.	Immunomodulatory protein and useful embodiments thereof
MXPA05003869A (es) *	2002-10-08	2005-06-22	Ares Trading Sa	El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
US7968684B2 (en) *	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
SI2267024T1 (sl)	2005-06-03	2012-09-28	Ares Trading Sa	Proizvodnja rekombinantnega IL-18 vezavnega proteina
ES2375831T3 (es)	2005-06-10	2012-03-06	Ares Trading S.A.	Procedimiento para la purificación de prote�?nas de unión a il-18.
CL2008002153A1 (es)	2007-07-24	2009-06-05	Amgen Inc	Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) *	2013-03-06	2017-11-07	Venkatesh R. Chari	Tactile graphic display
WO2023178192A1 (en)	2022-03-15	2023-09-21	Compugen Ltd.	Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0662003B1 (en) *	1992-09-02	2003-01-29	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US7141393B2 (en) *	1996-12-26	2006-11-28	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18-receptor proteins
IL131815A0 (en) *	1997-03-18	2001-03-19	Basf Ag	Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) *	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use

1999
- 1999-07-22 IL IL13104799A patent/IL131047A0/xx unknown
2000
- 2000-07-17 BR BR0012675-6A patent/BR0012675A/pt not_active IP Right Cessation
- 2000-07-17 MX MXPA02000838A patent/MXPA02000838A/es active IP Right Grant
- 2000-07-17 PL PL353732A patent/PL202477B1/pl unknown
- 2000-07-17 DK DK00944201T patent/DK1206274T3/da active
- 2000-07-17 HU HU0202107A patent/HU228780B1/hu unknown
- 2000-07-17 SK SK88-2002A patent/SK287522B6/sk not_active IP Right Cessation
- 2000-07-17 CA CA2380216A patent/CA2380216C/en not_active Expired - Lifetime
- 2000-07-17 DE DE1206274T patent/DE1206274T1/de active Pending
- 2000-07-17 PT PT00944201T patent/PT1206274E/pt unknown
- 2000-07-17 WO PCT/IL2000/000419 patent/WO2001007480A2/en active IP Right Grant
- 2000-07-17 CZ CZ20020195A patent/CZ302114B6/cs not_active IP Right Cessation
- 2000-07-17 AT AT00944201T patent/ATE363288T1/de active
- 2000-07-17 DE DE60035049T patent/DE60035049T2/de not_active Expired - Lifetime
- 2000-07-17 KR KR1020027000682A patent/KR100682219B1/ko active IP Right Grant
- 2000-07-17 JP JP2001512563A patent/JP4827352B2/ja not_active Expired - Lifetime
- 2000-07-17 EA EA200200189A patent/EA005419B1/ru not_active IP Right Cessation
- 2000-07-17 TR TR2002/00169T patent/TR200200169T2/ unknown
- 2000-07-17 NZ NZ516535A patent/NZ516535A/en not_active IP Right Cessation
- 2000-07-17 ES ES00944201T patent/ES2186596T3/es not_active Expired - Lifetime
- 2000-07-17 EE EEP200200032A patent/EE04838B1/xx unknown
- 2000-07-17 UA UA2002021472A patent/UA73745C2/uk unknown
- 2000-07-17 EP EP00944201A patent/EP1206274B1/en not_active Expired - Lifetime
- 2000-07-17 AU AU58432/00A patent/AU782478B2/en not_active Expired
- 2000-07-17 CN CNB008106894A patent/CN1173736C/zh not_active Expired - Lifetime
- 2000-07-21 AR ARP000103786A patent/AR024907A1/es unknown
2002
- 2002-01-11 NO NO20020153A patent/NO329827B1/no not_active IP Right Cessation
- 2002-01-16 BG BG106311A patent/BG65800B1/bg unknown
- 2002-01-16 ZA ZA200200390A patent/ZA200200390B/xx unknown
- 2002-01-17 IL IL147675A patent/IL147675A/en unknown
- 2002-11-11 HK HK02108154.3A patent/HK1048248B/zh not_active IP Right Cessation
2007
- 2007-07-06 US US11/825,548 patent/US7741276B2/en not_active Expired - Fee Related
- 2007-07-13 CY CY20071100938T patent/CY1107932T1/el unknown

Also Published As

Publication number	Publication date
AR024907A1 (es)	2002-10-30
NZ516535A (en)	2004-04-30
EP1206274A2 (en)	2002-05-22
CA2380216A1 (en)	2001-02-01
TR200200169T2 (tr)	2002-06-21
WO2001007480A3 (en)	2001-05-10
CZ2002195A3 (cs)	2002-06-12
EE200200032A (et)	2003-02-17
EE04838B1 (et)	2007-06-15
KR20020027493A (ko)	2002-04-13
DK1206274T3 (da)	2007-08-13
KR100682219B1 (ko)	2007-02-12
IL147675A (en)	2009-05-04
HU228780B1 (en)	2013-05-28
US7741276B2 (en)	2010-06-22
NO20020153D0 (no)	2002-01-11
IL131047A0 (en)	2001-01-28
HK1048248A1 (en)	2003-03-28
BR0012675A (pt)	2002-04-09
ZA200200390B (en)	2003-04-30
CZ302114B6 (cs)	2010-10-20
DE60035049D1 (de)	2007-07-12
NO329827B1 (no)	2011-01-03
ES2186596T1 (es)	2003-05-16
ATE363288T1 (de)	2007-06-15
CN1173736C (zh)	2004-11-03
HUP0202107A3 (en)	2005-01-28
DE1206274T1 (de)	2002-11-14
PL202477B1 (pl)	2009-06-30
SK882002A3 (en)	2002-07-02
AU782478B2 (en)	2005-08-04
HUP0202107A2 (en)	2002-10-28
WO2001007480A2 (en)	2001-02-01
MXPA02000838A (es)	2002-07-30
BRPI0012675B8 (pt)	2021-05-25
CN1364086A (zh)	2002-08-14
CA2380216C (en)	2012-01-31
AU5843200A (en)	2001-02-13
BG106311A (en)	2002-08-30
EA200200189A1 (ru)	2002-12-26
NO20020153L (no)	2002-03-11
EA005419B1 (ru)	2005-02-24
SK287522B6 (sk)	2011-01-04
US20080003216A1 (en)	2008-01-03
EP1206274B1 (en)	2007-05-30
ES2186596T3 (es)	2007-11-16
CY1107932T1 (el)	2013-09-04
HK1048248B (zh)	2005-04-22
JP2003505472A (ja)	2003-02-12
PL353732A1 (en)	2003-12-01
PT1206274E (pt)	2007-07-06
BG65800B1 (bg)	2009-12-31
JP4827352B2 (ja)	2011-11-30
BRPI0012675B1 (pt)	2001-02-01
DE60035049T2 (de)	2007-09-27

Publication	Publication Date	Title
Fazel Modares et al.	2019	IL‐6 trans‐signaling controls liver regeneration after partial hepatectomy
Graves	1999	The potential role of chemokines and inflammatory cytokines in periodontal disease progression
Bi et al.	2017	Key triggers of osteoclast-related diseases and available strategies for targeted therapies: a review
Lasky et al.	2000	Interstitial fibrosis and growth factors.
Lee et al.	2010	IL-1 plays an important role in the bone metabolism under physiological conditions
Bienkowski et al.	1995	Control of collagen deposition in mammalian lung
Feldmann et al.	2001	Cytokine blockade in rheumatoid arthritis
AU2015231777B2 (en)	2017-08-03	IL-21 antibodies
Brennan et al.	1995	TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action
TW201006926A (en)	2010-02-16	Agent for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory T cells
US20080003216A1 (en)	2008-01-03	Use of interleukin-18 inhibitors to inhibit tumor metastasis
Hsu et al.	2006	Influence of interleukin-6 on the invasiveness of human colorectal carcinoma
JP2006514057A (ja)	2006-04-27	哺乳類のサイトカイン；関連試薬の使用
Gowen	1992	Interleukin 1 and tumor necrosis factor
Hooper et al.	1995	IL-6 upregulates protein S expression in the HepG-2 hepatoma cells
Choy	2008	Inhibiting interleukin-6 in rheumatoid arthritis
SA92120509B1 (ar)	2005-11-23	تآزر وتضافر (tnf) مع il-4
Candela et al.	1993	Fibroblast growth factor increases TNFα-mediated prostaglandin E 2 production and TNFα receptor expression in human fibroblasts
KR101769122B1 (ko)	2017-08-17	케모카인 발현 조절제
Lowin	2020	Positive and negative cooperativity of TNF and Interferon-[ypsilon] in regulating synovial fibroblast function and B cell survival in fibroblast/B cell co-cultures
Zhang et al.	2013	Modulation of PAR expression and tryptic enzyme induced IL-4 production in mast cells by IL-29
HALAKA	2022	Development of Remote Inflammation through Interneuron Network in the Spinal Cord
Pinijpaitoon	2005	THE EFFECT OF INTERLEUKIN-6 ON THE EXPRESSION OF RECEPTOR ACTIVATOR OF NF-κB LIGAND, OSTEOPROTEGERIN AND MACROPHAGE COLONY STIMULATING FACTOR IN HUMAN DENTAL PULP FIBROBLAST